1. Home
  2. BNKK vs KPRX Comparison

BNKK vs KPRX Comparison

Compare BNKK & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNKK

Bonk Inc.

HOLD

Current Price

$0.45

Market Cap

9.4M

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$0.74

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNKK
KPRX
Founded
2018
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4M
10.6M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BNKK
KPRX
Price
$0.45
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 80.2K
69.8K
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,117,309.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 201.63
N/A
52 Week Low
$0.47
$0.78
52 Week High
$155.05
$2.91

Technical Indicators

Market Signals
Indicator
BNKK
KPRX
Relative Strength Index (RSI) 21.65 14.43
Support Level N/A N/A
Resistance Level $1.47 $2.66
Average True Range (ATR) 0.10 0.14
MACD -0.05 -0.06
Stochastic Oscillator 0.73 0.12

Price Performance

Historical Comparison
BNKK
KPRX

About BNKK Bonk Inc.

Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: